Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile
Crossref DOI link: https://doi.org/10.1136/bmjebm-2019-111328
Published Online: 2020-04-24
Published Print: 2021-08
Update policy: https://doi.org/10.1136/crossmarkpolicy
Storebø, Ole Jakob https://orcid.org/0000-0003-0204-7745
Gluud, Christian
Funding for this research was provided by:
Psychiatric Research Unit, Region Zealand Psychiatry, Denmark
Copenhagen Trial Unit, Centre for Clinical Intervention Research
